KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Shares Issued (2017 - 2025)

Bionano Genomics' Shares Issued history spans 7 years, with the latest figure at $9000.0 for Q1 2025.

  • For Q1 2025, Shares Issued changed N/A year-over-year to $9000.0; the TTM value through Sep 2025 reached -$37.7 million, down 139.54%, while the annual FY2024 figure was $11000.0, 99.98% down from the prior year.
  • Shares Issued for Q1 2025 was $9000.0 at Bionano Genomics, up from -$37.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $328.6 million in Q1 2021 and bottomed at -$318.6 million in Q3 2021.
  • The 5-year median for Shares Issued is $46000.0 (2023), against an average of $6.5 million.
  • The largest YoY upside for Shares Issued was 39902.9% in 2024 against a maximum downside of 165.45% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$61000.0 in 2021, then skyrocketed by 37585.25% to $22.9 million in 2022, then surged by 151.92% to $57.6 million in 2023, then crashed by 165.45% to -$37.7 million in 2024, then soared by 100.02% to $9000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Shares Issued are $9000.0 (Q1 2025), -$37.7 million (Q4 2024), and $10.1 million (Q3 2024).